"FDA Gives Green Light to Eli Lilly's Zepbound: A Breakthrough Weight Loss Medication"
TL;DR Summary
The FDA has approved Zepbound (tirzepatide) injection for chronic weight management in adults with obesity or overweight and at least one weight-related condition. Zepbound activates receptors in the intestine to reduce appetite and food intake. It is administered once weekly via injection and has been shown to significantly reduce body weight in clinical trials. However, it can cause side effects such as nausea and diarrhea. Zepbound should not be used in patients with a history of medullary thyroid cancer or severe gastrointestinal disease. It should also not be used in combination with certain medications.
- FDA Approves New Medication for Chronic Weight Management FDA.gov
- Zepbound: FDA approves Eli Lilly’s diabetes drug Mounjaro for obesity under new name CNN
- FDA approves Eli Lilly's tirzepatide for weight loss, paving way for wider use of blockbuster drug CNBC
- FDA approves Eli Lilly’s Zepbound, a weight loss drug similar to Ozempic and Wegovy NBC News
- FDA approves new obesity drug from Eli Lilly named Zepbound The Washington Post
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
4 min
vs 5 min read
Condensed
90%
938 → 94 words
Want the full story? Read the original article
Read on FDA.gov